Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults

Friend, Brian D.; Schiller, Gary J.

doi:10.1016/j.blre.2017.09.005

Cited by 14 publications

(11 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, there is room for improvement of patients outcome after pediatric type therapy in AYA with Ph‐neg ALL, and according to our results, this improvement is especially necessary for YA . The more extensive use of conventional drugs such as PEG‐asparaginase together with the early incorporation of immunotherapeutic approaches with naked (anti CD20), immunoconjugated (inotuzumab ozogamicin), or bispecific (blinatumomab) monoclonal antibodies which have proven effective in relapsed/refractory or MRD positive patients might contribute to improve the quality of remission and decreased the relapse rate observed in our study.…”

Section: Discussionmentioning

confidence: 88%

“…[31][32][33] Finally, incorporation of targeted kinase inhibitors to pediatric type chemotherapeutic regimens for specific subtypes of ALL such as BCR-ABL like might further contribute to overcome the resistance to therapy and improve survival of this particularly difficult to treat subgroup of ALL patients. 26…”

Section: Discussionmentioning

confidence: 99%

“…Bone marrow MRD levels were assessed at each participating center in CR patients at: i) end of induction (weeks 5-6) in CR patients, ii) end of consolidation/reinduction (weeks [19][20], iii) end of the fourth reinduction cycle (weeks [25][26], and iv) end of maintenance (week 106-108) using a 4-color multiparameter flow cytometry (FCM) approach with a limit of detection of 10 -4 .…”

Section: Minimal Residual Disease Assessmentmentioning

confidence: 99%

“…Methods: This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. Results: From 2008From to 2018 and 51 young adults [YA,[19][20][21][22][23][24][25][26][27][28][29][30], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%.…”

mentioning

confidence: 99%

See 3 more Smart Citations

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

et al. 2020

View full text Add to dashboard Cite

Background Pediatric‐based or ‐inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome‐negative (Ph‐neg) acute lymphoblastic leukemia (ALL). Methods This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15‐30 years with standard‐risk (SR) ALL. Results From 2008 to 2018, 89 patients (38 adolescents [15‐18 years] and 51 young adults [YA, 19‐30 years], median age: 20 [15‐29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty‐two patients were transferred to a high‐risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high‐level of end‐induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%‐47%), with significant differences between adolescents and YA: 13% (4%‐28%) vs 52% (34%‐67%), P = .012. No treatment‐related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5‐year overall survival (OS) was 74% (95%CI: 63%‐85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%‐100%) vs 63% (46%‐80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%‐47%] vs 37% [14%‐61%]; OS: 78% [66%‐90%] vs 61% [31%;91%]). Conclusion A full pediatric trial is feasible and effective for AYA with Ph‐neg, SR‐ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Minimal Residual Disease Assessmentmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The intrinsic biology of AYA disease is unique from other groups and in need of further clinical trials, and basic biologic and translational research. This would allow for the development of novel therapeutic agents and regimens specific to AYA . There is much debate about how to effectively maximize AYA treatment.…”

Section: Introductionmentioning

confidence: 99%

Future health of AYA survivors

Burkart

Sanford

Dinner

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Adolescent and young adult (AYA) oncology patients (ages 15–39) have been identified as a group with healthcare disparities including gaps and challenges in diagnosis, access to care, research, clinical trial participation, and cure rates. Like other patient groups with cancer or other chronic illnesses, disparities can lead to poor future health and outcomes, which is a well‐recognized concern within the AYA population. Cancer is the leading disease‐related cause of death in this age range. Numerous interested groups including the National Cancer Institute have met to address the research and cancer care needs of AYAs. This review highlights how these gaps in care during and after treatment can affect future health of this population of patients. Access to care, models of survivorship care, and lack of provider education are discussed. Survivorship care and use of guidelines, and promotion of psychosocial support and health behaviors during treatment and beyond are essential to optimizing future health of AYA patients.

show abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Lv,

Sun,

Huang

2023

Pathogenesis and Treatment of Leukemia

View full text Add to dashboard Cite

Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults

Cited by 14 publications

References 83 publications

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

Future health of AYA survivors

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About